Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 2/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11650920 | 0.86 | CA12 (0.49) | HPGDALDH1A1TDP1CASP6NSD2 | |
| SCHEMBL11521960 | 0.84 | TSHR (0.42) | HPGDALDH1A1TDP1CASP6NSD2 | |
| SCHEMBL10351830 | 0.84 | NSD2 (0.53) | HPGDALDH1A1TDP1CASP6NSD2 | |
| SCHEMBL11520955 | 0.84 | TSHR (0.42) | HPGDALDH1A1TDP1CASP6NSD2 | |
| SCHEMBL11521070 | 0.83 | TSHR (0.41) | HPGDALDH1A1TDP1CASP6NSD2 | |
| SCHEMBL10350683 | 0.80 | NSD2 (0.53) | HPGDALDH1A1TDP1CASP6NSD2 | |
| SCHEMBL596924 | 0.80 | L3MBTL1 (0.53) | HPGDALDH1A1TDP1CASP6NSD2 | |
| SCHEMBL11581091 | 0.79 | CASP6 (0.53) | HPGDALDH1A1TDP1CASP6NSD2 | |
| SCHEMBL3201792 | 0.78 | ALDH1A1 (0.58) | HPGDALDH1A1TDP1CASP6NSD2 | |
| SCHEMBL7898997 | 0.78 | NSD2 (0.42) | HPGDALDH1A1TDP1CASP6NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9457054-B2 | Method for using a Bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions | BAYER CROPSCIENCE LP (US) | 2016-10-04 | — | — | US | disclosed |
| EP-2547348-B1 | METHOD FOR USING A BACILLUS SUBTILIS STRAIN FOR PROPHYLAXIS AND TREATMENT OF GASTRO-INTESTINAL CONDITIONS | BAYER CROPSCIENCE LP (US) | 2015-05-20 | — | — | EP | disclosed |
| EP-2547348-A1 | METHOD FOR USING A BACILLUS SUBTILIS STRAIN FOR PROPHYLAXIS AND TREATMENT OF GASTRO-INTESTINAL CONDITIONS | Agraquest, Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20120328571-A1 | Method for Using a Bacillus Subtilis Strain for Prophylaxis and Treatment of Gastro-Intestinal Conditions | AGRAQUEST, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2011116155-A1 | METHOD FOR USING A BACILLUS SUBTILIS STRAIN FOR PROPHYLAXIS AND TREATMENT OF GASTRO-INTESTINAL CONDITIONS | AGRAQUEST, INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| US-7960544-B2 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| EP-2123277-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE | Meiji Seika Kaisha Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090264653-A1 | USEFUL INDOLE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| EP-1956914-A2 | THE USE OF BACILLUS PB6 FOR THE PROPHYLAXIS OR TREATMENT OF GASTROINTESTINAL AND IMMUNO-RELATED DISEASES | KEMIN INDUSTRIES, INC. (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20080057047-A1 | Use of bacillus amyloliquefaciens PB6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases | BANK OF AMERICA, N.A., AS COLLATERAL AGENT | 2008-03-06 | — | — | US | disclosed |
| EP-1185696-A1 | ANTISENSE OLIGONUCLEOTIDE MODULATION OF HUMAN PROTEIN KINASE C-DELTA EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-1119643-A1 | ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-$g(a) (TNF-$g(a)) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2001-08-01 | — | — | EP | disclosed |
| US-6258790-B1 | Antisense modulation of integrin α4 expression | ISIS PHARMACEUTICALS, INC. | 2001-07-10 | — | — | US | disclosed |
| US-6235723-B1 | DISEASES SENSITIVE TO TUMOR NECROSIS FACTOR; ANTIDIABETIC AGENTS, ANTIARTHRITIC AGENTS, SKIN DISORDERS, ANTITUMOR AGENT | ISIS PHARMACEUTICALS , INC. | 2001-05-22 | — | — | US | disclosed |
| US-6228642-B1 | NUCLEOTIDE SEQUENCES; ANTIINFLAMMATORY/ANTIDIABETIC AGENTS; ANTIARTHRITIC AGENTS; TREATMENT OF HEPATITIS AND AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS, CROHN'S DISEASE, PANCREATITIS, MULTIPLE SCLEROSIS, AND ATOPIC DERMATITIS | ISIS PHARMACEUTICALS, INC. | 2001-05-08 | — | — | US | disclosed |
| WO-2000070091-A1 | ANTISENSE OLIGONUCLEOTIDE MODULATION OF HUMAN PROTEIN KINASE C-δ EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| EP-0360848-B2 | Use of a gold bath for the preparation of dental prosthesis | WIELAND EDELMETALLE (DE) | 2000-07-12 | — | — | EP | disclosed |
| US-6080580-A | ANTIINFLAMMATORY/ANTIDIABETIC/ANTIARTHRITIC AGENTS; DIAGNOSIS AND THERAPY OF INFLAMMATION AND AUTOIMMUNE DISEASES; RHEUMATOID ARTHRITIS, CROHN'S DISEASE, PANCREATITIS, MULTIPLE SCLEROSIS, ATOPIC DERMATITIS, HEPATITIS | ISIS PHARMACEUTICALS INC. (US) | 2000-06-27 | — | — | US | disclosed |
| WO-2000020645-A1 | ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-α (TNF-α) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
| US-5968826-A | OLIGONUCLEOTIDE FROM 8 TO 30 NUCLEOBASES IN LENGTH; FOR ANTIMETASTASIS/ANTITUMOR/ANTIINFLAMMATORY/ANTIARTHRITIC AGENTS; DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISORDERS, CROHN'S DISEASE, MULTIPLE SCLEROSIS AND OTHERS | ISIS PHARMACEUTICALS INC. (US) | 1999-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264653-A1 | USEFUL INDOLE COMPOUNDS | FAAH, FAAH2, AANAT | HPGD 224/4885ALDH1A1 178/4885TDP1 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.